«The good news is that we discovered that a subset of patients who had both high tumor mutation burden and high PDL - 1 positive status did experience a significant benefit from immunotherapy,» says Carbone. (sciencedaily.com)
Patients with both high tumor mutation burden and high PDL - 1 positive status had a 75 percent response rate compared with a 16 percent response rate to immunotherapy among patients with low mutation burden and low PDL - 1. (sciencedaily.com)
«First - line immunotherapy treatment can improve survival for subset of lung cancer patients: Results of phase III global clinical trial show that 75 percent of stage IV lung cancer patients with both complex tumor mutations and PDL - 1 positive status respond to nivolumab.» (sciencedaily.com)